NEW AMBRX BIOPHARMA INC (AMAM) Stock Analyst Earnings Estimates
NASDAQ:AMAM - Nasdaq - US6418711080 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 13.67M 32.59% | 7.46M -45.43% | 7.4M -0.80% | 2.497M -66.26% | 1.742M -30.24% | 5.135M 194.78% | 4.188M -18.44% | 29.663M 608.29% | 169.53M 471.52% | 334.87M 97.53% | 583.3M 74.19% | |
| EBITDA YoY % growth | -11.18M 45.25% | -62.27M -456.98% | -64.94M -4.29% | -70.731M -8.92% | -102.754M -45.27% | -75.893M 26.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.12M 41.61% | -64.42M -391.01% | -66.74M -3.60% | -80.348M -20.39% | -107.309M -33.55% | -114.651M -6.84% | -166.988M -45.65% | -168.817M -1.10% | -71.412M 57.70% | 45.269M 163.39% | 231.73M 411.90% | |
| Operating Margin | -95.98% | -863.54% | -901.89% | -3,217.79% | -6,160.09% | -2,232.74% | -3,987.31% | -569.12% | -42.12% | 13.52% | 39.73% | |
| EPS YoY % growth | N/A | N/A | N/A 36.03% | -0.77 -159.66% | -1.64 -113.40% | -0.78 52.35% | -0.97 -24.51% | -0.91 6.29% | 0.23 125.75% | 1.17 397.09% | 2.05 75.52% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 -95.00% | -0.19 | -0.19 45.43% | -0.21 42.87% | -0.22 -9.10% |
| Revenue Q2Q % growth | 835.258K -81.40% | 586.5K 2,832.50% | 586.5K -47.63% | 714K 1,328.00% | 714K -14.52% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.757M 17.22% | -21.933M -36.82% | -22.412M -16.91% | -24.422M 4.72% | -25.055M -10.10% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | -0.37 -303.05% | -0.14 | -0.23 | -159.10% |
| Q2 2023 Q2Q % growth | -0.35 73.68% | -0.10 | -0.25 | -261.73% |
| Q4 2022 Q2Q % growth | -11.11% | -0.10 | % | |
| Q3 2022 Q2Q % growth | -12.50% | -0.09 | % | |
| Q2 2022 Q2Q % growth | -1.33 -1,762.75% | -0.09 | -1.24 | -1,348.80% |
| Q1 2022 Q2Q % growth | -100.00% | -0.08 | % |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | 50K | 780.688K | -730.688K | -93.60% |
| Q2 2023 Q2Q % growth | 1.12M -61.51% | 633.563K | 486.437K | 76.78% |
| Q1 2023 Q2Q % growth | 20K -98.76% | % | ||
| Q4 2022 Q2Q % growth | 4.49M 93.53% | % | ||
| Q2 2022 Q2Q % growth | 2.91M -43.27% | 1.948M | 962K | 49.38% |
| Q1 2022 Q2Q % growth | 1.61M -60.54% | 1.907M | -297K | -15.57% |
| Q4 2021 Q2Q % growth | 2.32M | 4.432M | -2.112M | -47.65% |
| Q2 2021 Q2Q % growth | 5.13M -20.83% | 4.08M | 1.05M | 25.74% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 51.11% | 0% | 0% |
| Revenue | 0% | 72.15% | 0% | 65.91% |